Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant- induced hyperlocomotion

Neuropsychopharmacology

Volumn 19, Issue 2, 1998, Pages 105-113

  Jentsch, J David ^a   Taylor, Jane R ^a   Roth, Robert H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dizocilpine; Nucleus accumbens; Prefrontal cortex; Psychotomimetic; Schizophrenia; Working memory

Indexed keywords

DEXAMPHETAMINE; DIZOCILPINE; DOPAMINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; PSYCHOSTIMULANT AGENT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STRESS;

3,4-DIHYDROXYPHENYLACETIC ACID; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; HALOPERIDOL; LIMBIC SYSTEM; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL; TIME FACTORS;

EID: 0031808409     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00004-9     Document Type: Article

References (63)

1. Andreasen N.C., Rezai K., Alliger R., Swayze V.W., Flaum M., Kirchner P., Cohen G., O'Leary D.S. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Arch Gen Psychiatry. 49:1992;943-958.
2. Angrist B., Gershon S. Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects. Adv Biochem Pharmacol. 16:1977;667-680.
3. Banks K.E., Gratton A. Possible involvement of medial prefrontal cortex in amphetamine-induced sensitization of mesolimbic dopamine function. Eur J Pharmacol. 282:1994;157-167.
4. Bowers M.B., Hoffman F.J. Homovanillic acid in rat caudate and prefrontal cortex following phencyclidine and amphetamine. Psychopharmacol. 84:1984;136-137.
5. Brozoski T.J., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 205:1979;929-931.
6. Bunney B.G., Bunney W.E. Jr., Carlsson A. Schizophrenia and glutamate. Bloom F.E., Kupfer D.J. Psychopharmacology, the Fourth Generation of Progress. 1994;1205-1214 Raven, New York.
7. Chambers R.A., Moore J., McEvoy J.P., Levin E.D. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology. 15:1996;587-594.
8. Cosgrove J., Newell T.G. Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol. 47:1991;159-169.
9. Daniel D.G., Berman K.F., Weinberger D.R. The effect of apomorphine on regional cerebral blood flow in schizophrenia. J Neuropsych. 1:1989;377-384.
10. Daniel D.G., Weinberger D.R., Jones D.W., Zigun J.R., Coppola R., Handel S., Bigelow L.B., Goldberg T.E., Berman K.F., Kleinman J.E. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 11:1991;1907-1917.
11. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia. A review and reconceptualization Am J Psychiatry. 148:1991;1474-1486.
12. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex. Interactions of central dopamine systems and the pathogenesis of schizophrenia J Neural Transm. 36:1992;61-89.
13. Deutch A.Y., Clark W.A., Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res. 521:1990;311-315.
14. Deutch AY, Roth RH (1990): The determinants of stress-induced activation of the prefrontal cortical dopamine system. In Vylings HBM, Eden CGV, DeBruim JPC, Corner MA, Feenstra MGP (eds), The Prefrontal Cortex: Its Structure, Function, and Pathology. Amsterdam, Elsevier, pp 367-403.
15. Deutch A.Y., Tam S.Y., Freeman A.S., Bowers M.B., Roth R.H. Mesolimbic and mesocortical dopamine activation induced by phencyclidine. Contrasting pattern to striatal response Eur J Pharmacol. 134:1987;257-264.
16. Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S.J., Grasby P.M. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature. 378:1995;180-182.
17. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine, and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Rev. 20:1995;250-267.
18. Fey E.T. The performance of young schizophrenics and young normals on the Wisconsin Card Sorting Test. J Consult Psychol. 15:1951;311-319.
19. Goldberg T.E., Weinberger D.R. Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophr Bull. 14:1988;179-183.
20. Goldman-Rakic P.S. Circuitry of the frontal cortex and the regulation of behavior by representational knowledge. Plum F., Mountcastle V. Handbook of Physiology, Volume V, The Nervous System. 1987;373-417 American Physiological Society, Bethesda, MD.
21. Goldman-Rakic PS (1991): Prefrontal cortical dysfunction in schizophrenia: The relevance of working memory. In Carroll BJ, Barret JE (eds), Psychopathology and the Brain. New York, Raven, pp 1-23.
22. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity. A hypothesis for the etiology of schizophrenia Neurosci. 41:1991;1-24.
23. Gur R.E., Resnick S.M., Gur R.C. Laterality and frontality of cerebral blood flow and metabolism in schizophrenia. Relationship to symptom specificity Psychiatry Res. 27:1989;325-334.
24. Healy D.J., Meador-Woodruff J.H. Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesocorticolimbic systems. Brain Res. 708:1996;38-44.
25. Hertel P., Mathe J.M., Nomikos G.G., Iurlo M., Mathe A.A., Svensson T.H. Effects of d-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav Brain Res. 72:1996;103-114.
26. Hertzman M., Reba R.C., Kotlyarove E.V. Single photon emission computerized tomography in phencyclidine and related drug abuse. Am J Psychiatry. 147:1990;255-256.
27. Ital T., Keskiner A., Kiremitci N., Holden J.M.C. Effect of phencyclidine in chronic schizophrenics. Can Psychiatric Assoc J. 12:1967;209-212.
28. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
29. Jentsch J.D., Roth R.H. Differential effects of acute and repeated phencyclidine administration on prefrontal cortical dopamine. relevance to schizophrenia Soc Neurosci Abstr. 22:1996;1320.
30. Jentsch J.D., Elsworth J.D., Redmond D.E. Jr., Roth R.H. Phencyclidine increase forebrain monoamine metabolism in rats and monkeys. Modulation by the isomers of HA966 J Neurosci. 17:1997;1769-1776. a.
31. Jentsch J.D., Tran A., Le D., Youngren K.D., Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology. 17:1997;92-99. b.
32. Jentsch J.D., Redmond D.E. Jr., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive dysfunction and cortical dopamine deficits in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955. c.
33. Jentsch JD, Taylor JR, Elsworth JD, Redmond DE, Jr, Tran A, Le D, Kudelko KT, Roth RH (1997d): Prefrontal cortical cognitive and dopamine deficits in rats and monkeys after subchronic PCP exposure. Soc Neurosci Abstr 23:1930.
34. Kerwin R.W., Murray R.M. A developmental perspective on the pathology and neurochemistry of the temporal lobe in schizophrenia. Schizophr Res. 7:1992;1-12.
35. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers B.M., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses Arch Gen Psychiatry. 51:1994;199-214.
36. Lahti A.C., Koffel B., Laporte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1994;9-19.
37. Lannes B., Micheletti G., Warter J.-M., Kempf E., Di Scala G. Behavioral, pharmacological, and biochemical effects of acute and chronic administration of ketamine in the rat. Neurosci Lett. 128:1991;177-181.
38. Laruelle M., Abi-Dargham A., Van Dyck C., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Finugado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 93:1996;9235-9240.
39. Lee M.A., Thompson P.A., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 55:1994;82-87.
40. Liddle P.F., Friston K.J., Frith C.D., Hirsch S.R., Jones T., Frackowiak R.S.J. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry. 160:1992;179-186.
41. Lipska B.K., Jaskiw G.E., Weinberger D.R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal hippocampal damage. A potential animal model of schizophrenia Neuropsychopharmacology. 9:1993;67-75.
42. Lipska B.K., Weinberger D.R. Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Dev Brain Res. 75:1993;75-222.
43. Lipska B.K., Weinberger D.R. Subchronic treatment with haloperidol or clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology. 10:1994;199-205.
44. Lipska B.K., Chrapusta S.J., Egan M.F., Weinberger D.R. Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild chronic stress and haloperidol treatment. Synapse. 20:1995;125-130. a.
45. Lipska B.K., Swerdlow N.R., Geyer M.A., Jaskiw G.E., Braff D.L., Weinberger D.R. Neonatal excitotoxic hippocampal damage in rats causes postpubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology. 122:1995;35-43. b.
46. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelly R. Study of a new schizophrenic-like drug - Sernyl. Arch Neurol Psychiatry. 81:1959;363-369.
47. Meltzer H.Y., Sturgeon R.D., Simonovic M., Fessler R.G. Phencyclidine as an indirect dopamine agonist. Psychopharmacol Bull. 16:1980;62-65.
48. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 385:1997;634-636.
49. Park S., Holzman P.S. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry. 49:1992;975-982.
50. Pearlson G.D. Psychiatric and medical syndromes associated with phencyclidine (Pcp) abuse. The Johns Hopkins Med J. 148:1981;25-33.
51. Roberts A.C., De Salvia M.A., Wilkinson L.S., Collins P., Muir J.L., Everitt B.J., Robbins T.W. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analogue of the Wisconsin Card Sort Test. Possible interactions with subcortical dopamine J Neurosci. 14:1994;2531-2544.
52. Robbins T.W. The case for frontostriatal dysfunction in schizophrenia. Schizophr Bull. 16:1990;391-402.
53. Rosin D.L., Clark W.A., Goldstein M., Roth R.H., Deutch A.Y. Effects of 6-hydroxydopamine lesions of the prefrontal cortex on tyrosine hydroxylase activity in subcortical dopamine systems in the rat. Neuroscience. 48:1994;831-839.
54. Sams-Dodd F. Phencyclidine-induced stereotyped behavior and social isolation in rats. A possible animal model of schizophrenia Behav Pharmacol. 7:1996;3-23.
55. Sams-Dodd F., Lipska B.K., Weinberger D.R. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behavior in adulthood. Psychopharmacology. 132:1997;303-310.
56. Seidman L.J., Yurgelun-Todd D., Kremen W.S., Woods B.T., Goldstein J.M., Faraone S.V., Tsuang M.T. Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia. Biol Psychiatry. 35:1994;235-246.
57. Shenton M.E., Kikinis R., Jolesz F.A., Pollak S.D., LeMay M., Wible C.G., Hokama H., Martin J., Metcalf D., Coleman M.et al. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. New Engl J Med. 327:1992;604-612.
58. Steinpreis R.E. The behavioral and neurochemical effects of phencyclidine in humans and animals. Some implications for modeling psychosis Behav Brain Res. 74:1996;45-55.
59. Steinpreis R.E., Sokolowski J.D., Papanikolaou A., Salamone J.D. The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat. Pharmacol Biochem Behav. 47:1994;579-585.
60. Weinberger D.R., Berman K.F. Prefrontal function in schizophrenia. Confounds and controversies Phil Trans R Soc Lond B. 351:1996;1495-1503.
61. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence Arch Gen Psychiatry. 43:1986;114-125.
62. Weinberger D.R., Berman K.F., Illowsky B.P. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism Arch Gen Psychiatry. 45:1988;609-615.
63. Wu J.C., Buchsbaum M.S., Bunney W.E. Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Jpn J Psychopharmacol. 11:1991;47-48.